# Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

> **NCT01440686** · PHASE1 · COMPLETED · sponsor: **HanAll BioPharma Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** Somatropin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01440686
- **Lead sponsor:** HanAll BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01440686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01440686, "Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01440686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*